There are several provisions, but the one that I think is most troubling, I guess from an ethical point of view, is the extension of data exclusivity. This basically means that a generic company doesn't have access to the information, the clinical trials, on which a drug that's coming off patent was originally patented for....
Without that information being made available relatively quickly, they're forced either not to produce a generic version of the drug, or to subject people again to clinical trials for a drug that we already know works. To give people placebos when you know that they actually need the drug seems to me rather unethical. The longer you have this arrangement where they have to wait, the longer, obviously, it's going to take for generics to get on the market, and the more costly it is for those countries.
This is a big barrier that, as the TPP is implemented, will be raised as a result of what is being proposed.